Venus Remedies gains 5% on Saudi Arabia's marketing approval for anti-coagulant drug
The company has said it has so far secured marketing authorisations from Saudi Arabia for six antibiotics meant for intensive care units and three oncology products
VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies on expansion spree in Gulf, gets Saudi marketing approval for Enoxaparin in PFS. VENUS REMEDIES LTD. - 526953 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
AGM E-voting results along with scrutinizer report. VENUS REMEDIES LTD. - 526953 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Proceedings of Annual General Meeting held today. VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Venus Remedies launches its flagship R&D drug Elores in Oman. VENUS REMEDIES LTD. - 526953 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of UFR as on 30.06.2023. VENUS REMEDIES LTD. - 526953 - Unaudited Financial Results For The Quarter Ended On 30.06.2023.
Unaudited financial results for the quarter ended on 30.06.2023. VENUS REMEDIES LTD. - 526953 - Board Meeting Outcome for Outcome Of Board Meeting Dated 14.08.2023
This has reference to the meeting of Board of Directors held on 14th August 2023 inter alia considered and approved the Unaudited Financial Results for the period ended on 30th June 2023 along with Limited Review report. Unaudited Financial Results for the period ended on 30th June 2023 along with Limited Review report are enclosed herewith. Meeting commenced at 04:30 pm and concluded at 07.05 pm. Kindly take the above information on your record. VENUS REMEDIES LTD. - 526953 - Board Meeting Intimation for Notice Of Board Meeting To Be Held On 14Th August 2023.
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 14th August 2023 inter alia: 1. To consider and approve Unaudited Standalone and Consolidated Financial Results for the quarfer ended on 30th June 2023. 2. Any other business with the permission of Chair.
Venus Remedies gets market authorisations for cancer drugs from Philippines, Praguay, Georgia, Moldova
With this, the company has secured 506 marketing approvals for its oncology products across 76 countries.